Author:
Salihoglu A.,Elverdi T.,Karadogan I.,Paydas S.,Ozdemir E.,Erdem G.,Karadurmus N.,Akyol G.,Kaynar L.,Yegin ZA,Sucak G.,Ozkocaman V.,Topcuoglu P.,Ozcan M.,Birtas E.,Goker H.,Baslar Z.,Ferhanoglu B.
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference10 articles.
1. Skarbnik AP, Pro B (2013) Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma. Expert Rev Hematol 6(1):1–3. doi: 10.1586/ehm.12.71
2. Gualberto A (2012) Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin Investig Drugs 21(2):205–216. doi: 10.1517/13543784.2011.641532
3. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87(4):277–283. doi: 10.1007/s00277-007-0399-y
4. Kahraman D, Theurich S, Rothe A, Kuhnert G, Sasse S, Scheid C, Dietlein M, Drzezga A, von Bergwelt-Baildon M, Kobe C (2013) 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Leuk Lymphoma. doi: 10.3109/10428194.2013.819575
5. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献